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Abstract
Purpose of review-—The receptor for advanced glycation end products (RAGE) and several of 
its ligands have been implicated in the onset and progression of pathologies associated with aging, 
chronic inflammation, and cellular stress. In particular, the role of RAGE and its ligands in bone 
tissue during both physiological and pathological conditions has been investigated. However, the 
extent to which RAGE signaling regulates bone homeostasis and disease onset remains unclear. 
Further, RAGE effects in the different bone cells and whether these effects are cell-type specific is 
unknown. The objective of the current review is to describe the literature over RAGE signaling in 
skeletal biology as well as discuss the clinical potential of RAGE as a diagnostic and/or 
therapeutic target in bone disease.
Recent findings-—The role of RAGE and its ligands during skeletal homeostasis, tissue repair, 
and disease onset/progression is beginning to be uncovered. For example, detrimental effects of 
the RAGE ligands, advanced glycation end products (AGEs), have been identified for osteoblast 
viability/activity, while others have observed that low level AGE exposure stimulates osteoblast 
autophagy, which subsequently promotes viability and function. Similar findings have been 
reported with HMGB1, another RAGE ligand, in which high levels of the ligand are associated 
with osteoblast/osteocyte apoptosis, whereas low level/short-term administration stimulates 
osteoblast differentiation/bone formation and promotes fracture healing. Additionally, elevated 
levels of several RAGE ligands (AGEs, HMGB1, S100 proteins) induce osteoblast/osteocyte 
apoptosis and stimulate cytokine production, which is associated with increased osteoclast 
differentiation/activity. Conversely, direct RAGE ligand exposure in osteoclasts may have 
inhibitory effects. These observations support a conclusion that elevated bone resorption observed 
in conditions of high circulating ligands and RAGE expression are due to actions on osteoblasts/
osteocytes rather than direct actions on osteoclasts, although additional work is required to 
substantiate the observations.
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Summary-—Recent studies have demonstrated that RAGE and its ligands play an important 
physiological role in the regulation of skeletal development, homeostasis, and repair/regeneration. 
Conversely, elevated levels of RAGE and its ligands are clearly related with various diseases 
associated with increased bone loss and fragility. However, despite the recent advancements in the 
field, many questions regarding RAGE and its ligands in skeletal biology remain unanswered.
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Introduction
The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor 
belonging to the immunoglobulin receptor superfamily [1, 2]. RAGE binds numerous 
endogenous and exogenous ligands and plays a critical role in regulating the innate immune 
response [3]. Additionally, recent evidence suggests that RAGE signaling is involved in 
inflammation resolution, tissue homeostasis, and repair/regeneration following injury [1]. 
Despite this evidence, most studies have focused on the pathological role of RAGE 
signaling. RAGE is upregulated during the onset and progression of a variety of aging- and 
inflammation-associated diseases including diabetes, cancer, cardiovascular disease, 
neurodegeneration, and bone-related pathologies [4–6]. Based on these findings, the 
potential therapeutic effects of targeting RAGE and its ligands to treat/prevent inflammation-
associated pathologies in humans is being investigated. This is supported by the fact that 
global RAGE knockout (KO) mice are viable and do not exhibit profound phenotypic 
abnormalities [7]. Numerous small molecule RAGE inhibitors have been developed over the 
last decade, and their research and clinical utility has been evaluated [3, 8]. Further, the 
diagnostic potential of RAGE and its ligands as biomarkers for the progression and severity 
of various pathologies has also been demonstrated [2, 9–12].
In the skeleton, RAGE plays a role in regulating bone metabolism under physiological 
conditions and may contribute to various bone-related diseases [4]. However, the specific 
cell type that mediates RAGE signaling, and the downstream effects of RAGE activation on 
bone homeostasis and pathology, remain unclear. Further, the therapeutic potential of 
targeting RAGE and its ligands and their diagnostic potential as biomarkers of bone-related 
pathologies has not been elucidated. In this review, we cover the current knowledge on this 
topic and examine the bone cell type-specific roles of RAGE signaling during bone 
metabolism and turnover.
Biology of RAGE and its Ligands
Receptor structure and isoforms
RAGE is ~50kDa protein consisting of an extracellular N-terminal V-type (variable) and two 
C-type (constant) domains, a single transmembrane domain, and a C-terminal cytoplasmic 
tail [1, 3]. The extracellular V-type domain is the receptor ligand binding portion and the 
cytoplasmic tail is required for signal transduction, however, adaptor protein association is 
required for signal transduction [1, 13].
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Full-length (fl)-RAGE mRNA undergoes extensive alternative splicing that generates more 
than 20 isoforms, including membrane and soluble forms [14–16]. N-truncated RAGE is 
composed of the transmembrane and cytoplasmic domains, but lacks the V-type domain 
[14], whereas dominant negative RAGE contains the extracellular and transmembrane 
domains, but lacks the cytoplasmic domain, and is therefore able to bind ligands, but is 
unable to transduce signaling [16].
Further, two extracellular secreted forms of RAGE, endogenous secretory (es) and soluble 
(s) RAGE, have been identified [17]. esRAGE is generated by alternative splicing of RAGE 
mRNA, whereas sRAGE is released following proteolytic cleavage of fl-RAGE by 
ADAM10 and MMP9 [18]. Although the sRAGE isoforms lack the transmembrane and 
cytoplasmic domains, they retain their ligand binding ability, acting as decoy receptors 
preventing ligand binding to RAGE or other receptors [19]. Consistent with this notion, 
sRAGE treatment downregulates RAGE signaling and subsequently decreases inflammation 
[20, 21]. However, sRAGE administration can also stimulate signal transduction and induce 
an inflammatory response [22, 23].
RAGE signaling
RAGE is expressed in various cells types during tissue development, homeostasis, and 
regeneration/repair, suggesting a critical role of RAGE in these processes [1]. Upon ligand 
binding, RAGE activation stimulates downstream signaling pathways (NF-κB, AP-1, CREB, 
STAT3, NFAT) that induce cytokines/chemokines transcription, control cellular processes, 
and influence cell viability by regulating autophagy and apoptosis [1]. Cell type-related 
differences in adaptor protein signaling, as well as cell/tissue-specific gene transcription, are 
potential elements that contribute to cell type-specific effects of RAGE activation [24]. 
Additionally, factors such as metabolic status, reactive oxygen species (ROS) levels, and 
intra- and extracellular redox conditions, can also alter RAGE ligand properties and modify 
downstream signaling [1, 25, 26]. RAGE-ligand signaling and its downstream effects on 
skeletal biology are covered in more detail later in the review.
Aside from binding numerous ligands, RAGE activation alters numerous downstream 
signaling pathways in bone cells. In particular, RAGE is critical for αvβ3 integrin-mediated 
adhesion in osteoclasts [27]. Further, RAGE-deficient osteoclasts are not able to respond to 
vitronectin, a αvβ3-integrin ligand, and exhibit impaired PYK2 and ERK1/2 
phosphorylation. Additionally, RAGE-deficient osteoclasts have reduced integrin expression, 
which is needed for proper osteoclast maturation and adhesion; they also have decreased c-
Fos and NFATc-1 expression in response to M-CSF and RANKL signaling. Dia-1, a member 
of the formin family of proteins, also binds RAGE via an FH1 domain on the cytoplasmic 
tail of the receptor. This allows for signal transduction to elicit cellular migration using the 
GTP-ase activity of Rac-1 and Cdc42, known osteoclastogenic GTP-ases [13, 28]. In 
osteoblasts, AGE-RAGE activation increased Raf/MEK/ERK signaling, decreasing cell 
viability and activating beclin-1 and LC3B-mediated autophagy [29]. Further studies are 
needed to elucidate the multiple signaling pathways that might be activated by RAGE-ligand 
interaction, and the particular signaling cascade activated by different ligands in bone cells.
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RAGE Ligands
RAGE is a pattern recognition receptor (PRR) that binds numerous endogenous and 
exogenous ligands [1, 30]. Aside from RAGE, other PRRs include toll-like receptors 
(TLRs), mannose receptors (MR), and NOD-like receptors (NLR), which bind overlapping 
ligands [31]. RAGE binds endogenous damage-associated proteins (DAMPs), including 
advanced glycation end products (AGEs), high mobility group box 1 (HMGB1), S100 
calgranulin proteins, amyloid β peptide (Aβ), heat shock proteins (HSP), and macrophage 1 
antigen (Mac-1/CD11b), that are released extracellularly in response to cell stress and death 
[4, 19]. Elevated extracellular RAGE ligand levels stimulate RAGE expression, mainly 
through NF-κB activation [32]. RAGE expression is upregulated in multiple cell types/
tissues during the onset/progression of numerous pathological conditions [33]. In particular, 
RAGE expression and extracellular ligand levels play an important role in regulating bone 
metabolism and elevated RAGE-ligand signaling is associated with various pathologies 
characterized by reduced bone mass/strength [4]. Below we further detail the roles of the key 
RAGE-ligands during bone metabolism and pathology.
AGEs.—AGEs occur from aldose sugar-mediated non-enzymatic chemical modifications of 
proteins and lipids [30]. AGE formation and tissue accumulation increases during aging and 
conditions of hyperglycemia such as diabetes. Tissues containing long-lived proteins, such 
as collagen, and with low turnover are particularly vulnerable to such non-enzymatic 
modifications [34]. In bone, AGE accumulation alters the material properties and decreases 
toughness [35, 36]. Additionally, circulating AGEs can bind RAGE, as well as other 
receptors and stimulate signal transduction in various tissues/cell types [30]. AGE-RAGE 
signaling has been implicated in numerous aging-related pathologies [34]. In particular, it 
has been proposed that prolonged AGE signaling plays a role in the onset/progression of 
diabetic osteopenia and may also contribute to aging-related bone fragility [36].
HMGB1 (amphoterin).—HMGB1, first described as a chromatin-bound protein, is 
released by necrotic cells as a DAMP, and subsequently promotes monocyte recruitment and 
pro-inflammatory cytokine release [37]. HMGB1 signals through RAGE, and can also act 
through TLR4 and 2, producing a similar pro-inflammatory response, activating NF-κB 
through effectors such as TRAF6, IKKα, and IKKβ [38]. HMGB1/RAGE signaling 
promotes immune cell differentiation and proliferation [39], as well as cellular migration, 
probably in part due to the secretion of pro-inflammatory cytokines through NF-κB 
signaling [40]. HMGB1 is also extracellularly released by osteoclasts, osteoblasts, and 
osteocytes, which all express RAGE [41]. In primary osteoblasts and MC3T3-E1 
osteoblastic-like cells, parathyroid hormone (PTH) treatment attenuates HMGB1 release, 
whereas in rat UMR 106–01 osteosarcoma cells PTH increases its release. Interestingly, 
both the increased and decreased HMGB1 release from these different cell lines is mediated 
by adenylyl cyclase, highlighting the diversity and context-specific effects of PTH-signaling. 
In osteoclasts, epidermal growth factor-mediated HMGB1 release induces RANK expression 
via CD68 in patients with autoimmune disease, suggesting that HMGB1 promotes osteoclast 
differentiation in human diseases [42].
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S100 calgranulin proteins.—The S100 proteins, are a small (10–12kD), highly-
conserved family of proteins characterized by a unique Ca2+ binding motif [43]. S100 
proteins localize to specific cellular compartments and translocate upon Ca2+ signaling. 
S100 proteins signal through RAGE and/or TLR4, requiring Ca2+ to do so, and are released 
by leukocytes in high-inflammation disease states [44]. Different family members activate or 
inhibit the receptors in a tissue- and context-specific manner. Interestingly, S100 protein 
signaling via RAGE promotes the secretion of cytokines in endothelial cells and leukocytes 
through NF-kB signaling, resulting in a pro-inflammatory environment that contributes to 
disease pathology, for example, in chronic kidney disease [45]. In skeletal muscle, S100B 
promotes proliferation in low-density myoblast cultures, enhancing myogenic differentiation 
via p38/MAPK, [46] whereas in aging, S100B is increased and downregulates myogenic 
differentiation in skeletal muscle [46]. In bone, S100 proteins regulate skeletal metabolism 
through direct and indirect actions on bone cells, however more work is needed to 
understand the cell-type specific roles of S100 proteins [47, 48].
Amyloid Beta Fibrils (Aβ).—Amyloid precursor protein (APP), most famously studied in 
neurodegenerative diseases, aggregates into plaques as amyloid-β (Aβ) via enzymatic 
cleavage [49]. Aβ signals through RAGE, potentially due to its structural similarities to a 
glycoprotein [50]. In the brain, Aβ binding to RAGE signals through p38/MAPK and 
receptor-mediated protein uptake [51]. Aβ is also expressed in bone and influences bone cell 
activity. For example, γ secretase-dependent cleavage of APP alters osteoblast activity; and 
Aβ promotes RANKL-induced osteoclast differentiation via NF-κB, ERK, and calcium 
oscillation signaling [52]. Additionally, skeletal analysis in APPswe/Aβ transgenic mice 
found that Aβ regulates osteoclastogenesis and RAGE expression in an age-dependent 
manner [53]. Aβ peptide expression is also elevated in osteoporotic bone tissue, consistent 
with the pro-inflammatory/pathological effects of Aβ during aging and disease onset/
progression [54, 55]. Further, the antioxidant curculigoside attenuates memory and bone loss 
in APP/PS1 transgenic mice, highlighting a potential involvement of Aβ signaling in bone 
loss [56].
Physiological RAGE Signaling in Bone
Bone cells [mesenchymal stem cells (MSCs), osteoclasts, osteoblasts, and osteocytes] 
express RAGE and its expression is differentially regulated during cell proliferation, 
differentiation, and survival [4]. Further, studies in global RAGE KO mice have 
demonstrated the importance of RAGE in the regulation of bone accrual and turnover [57, 
58]. However, while it is clear that RAGE plays a critical role in the skeleton, the 
mechanisms underlying these effects and the cell-type specific roles of RAGE and its 
ligands in bone remain unclear.
Young (1–3-month-old) RAGE KO mice exhibit high bone mineral density (BMD), bone 
volume, and biomechanical strength compared to wildtype mice [57]. Consistently, whole 
body/vertebral BMD and vertebral cancellous bone volume are also higher in 4-month-old 
RAGE KO compared to wildtype mice [58]. However, femoral bone mass accrual was 
attenuated and femoral cancellous bone volume was reduced in the absence of RAGE. 
Further, RAGE KO mice maintain bone mass and exhibit reduced bone resorption following 
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ovariectomy (OVX) [59], but RAGE deficiency impaired PTH-induced increases in femur 
cancellous bone volume, whereas it did not prevent the effects of PTH on vertebral 
cancellous bone.
Consistent with the high bone mass of RAGE KO mice, in vivo and in vitro studies showed 
that osteoclast differentiation and activity are decreased in RAGE KO compared to wildtype 
mice [4, 57, 60]. Further, RAGE expression is increased during osteoclast differentiation and 
RANKL stimulates RAGE expression in osteoclasts in a time- and dose-dependent manner 
[4, 57]. Additionally, in vitro studies demonstrated that RANKL-mediated osteoclast 
differentiation/activity is attenuated in bone marrow cells isolated from RAGE KO mice and 
RAGE deficiency leads to morphological defects, which are associated with reduced 
osteoclast differentiation and bone resorption [60]. These osteoclast defects are due to 
defective αvβ3-dependent signaling and attenuated actin-based cytoskeletal organization in 
RAGE KO bone marrow-derived macrophages (BMMs) and pre-osteoclasts. Further, in vitro 
mechanistic studies demonstrated that RAGE is required for the signaling events that 
stimulate osteoclast differentiation and function, upon engagement of M-CSF and αvβ3 
integrin-signaling. However, whether RAGE controls integrin signaling at the 
transcriptional, cell surface, or intracellular level remains unknown [57, 60]. Overall, these 
findings highlight the important role that RAGE signaling plays in regulating osteoclast 
development and activity.
RAGE signaling also appears to play an important role in osteoblasts and osteocytes, 
although this topic has been less studied. Consistent with the decreased femoral cancellous 
bone accrual and altered architecture detected in the 4-month-old RAGE KO mice, the 
expression of several osteoblast-associated genes, ALP, Cola1, Runx2, and Osterix was 
decreased in femurs from these mice [58]. Further, global RAGE deficiency suppresses 
PPARα and its co-factor PGC1α, which leads to a pro-inflammatory phenotype in bones 
and osteoblasts from RAGE KO compared to control mice [61]. It should be noted that the 
meaning of the “pro-inflammatory phenotype” was not clearly described in the Biswas 
study, making it hard to draw conclusions about the osteoblastic effects of RAGE deficiency. 
In addition to these findings, preliminary work by our group found that in vitro 
mineralization is decreased in bone marrow cells from global RAGE KO compared to age-
matched wildtype control mice. While these findings point to an essential role of RAGE 
signaling in osteoblast metabolism and function, additional studies are needed to clearly 
elucidate RAGE roles in osteoblasts and the mechanisms mediating these effects. Further, 
more work is needed to determine whether RAGE signaling also regulates osteocyte 
viability/function.
Taken together, this evidence suggests that RAGE signaling plays an important role in 
regulating both osteoclast and osteoblast differentiation/activity. Further, RAGE signaling 
effects are both age-related and bone site-specific. Overall, while our understanding of the 
mechanisms that regulate the downstream effect of RAGE signaling in bone under both 
physiological and pathological conditions has advanced in recent years, many questions still 
remain unanswered.
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RAGE Ligand Regulation of Bone Metabolism
Low dose/intermittent exposure
Consistent with the inhibitory effects of genetic RAGE deficiency in osteoblasts, several 
studies have identified beneficial effects associated with RAGE ligand stimulation and 
signaling in MSCs and osteoblastic cells (Figure 1A). In particular, HMGB1 signaling in 
MSCs/osteoblasts promotes tooth socket bone healing in mice following a tooth extraction 
[62]. Further, HMGB1 stimulates cytokine release and promotes osteogenic MSC 
differentiation [63]. Consistent with the beneficial effects of HMGB1 on bone repair, 
treatment of bone fracture sites with HMGB1 and MSC-containing gelatin sponges enhances 
fracture repair [64]. Additionally, HMGB1 drives osteoblast migration and promotes fracture 
site vascularization, which in turn stimulates endochondral bone formation [39, 65]. 
Hypoxic-conditions also induce HMGB1 expression/release, which subsequently promotes 
osteoblast proliferation [66]. Moreover, recent studies found that low levels of AGEs have 
beneficial effects on osteoblasts. One study demonstrated that low levels of AGE-RAGE 
signaling stimulates autophagy and enhances osteoblast viability [29]. These findings 
highlight the possibility that under physiological conditions short-term or low level RAGE 
ligand exposure may have protective effects in bone cells. This notion is consistent with the 
idea that chronic rather than acute RAGE signaling induced by inflammation/cell stress 
leads to disease onset/progression.
High dose/chronic exposure
Despite the beneficial effects of low-dose/short-term RAGE ligand exposure, high-dose 
exposure negatively affects bone metabolism (Figure 1A). In particular, AGE treatment in 
MSCs prevents proliferation/differentiation into osteoblasts and inhibits mineralization [67]. 
Further, AGEs increase ROS generation, stimulate RAGE expression, and induce MSC 
apoptosis [68, 69]. Similar effects of AGEs have been observed in osteoblasts and 
osteocytes. In hFOB1.19 osteoblastic cells, AGEs stimulate mitochondrial dysfunction and 
apoptosis [70–72]. Consistently, AGE exposure inhibits osteoblast proliferation/
differentiation, decreases osteoblastic gene expression and suppresses mineralization and 
lysyl oxidase enzyme activity [73–76]. AGEs also stimulate apoptosis in MLO-Y4 
osteocytic cells [77] and promote pro-inflammatory cytokine release (IL-6, TNFa, RANKL, 
VEGFA) from osteoblasts and osteocytes [78–80]. Additionally, HMGB1 and S100A9 have 
similar effects on cell viability and cytokine production/release in osteoblasts and osteocytes 
[47, 48, 81].
In particular, work by our group demonstrated that apoptotic MLO-Y4 osteocytes release 
elevated levels of RANKL and HMGB1 and prevention of apoptosis or blockade of HMGB1 
actions attenuated RANKL expression/release [81]. Further, we found that conditioned 
media (CM) from apoptotic MLO-Y4 osteocytes induced osteoclast differentiation; and 
inhibition of apoptosis or blockade of HMGB1 actions in osteocytes attenuated these effects 
[81]. Further, inhibition of HMGB1 autocrine actions in osteocytes using neutralizing 
antibodies, followed by immune-precipitation (IP) to remove the antibody-HMGB1 
complexes from the CM blocked the increases in osteoclastogenesis induced by CM from 
apoptotic Cx43-deficient MLO-Y4 cells. On the other hand, IP removal of HMGB1 after 
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collecting the osteocytic CM did not prevent osteoclast differentiation. These findings 
suggest that HMGB1 autocrine actions on osteocytes, rather than direct actions on 
osteoclasts mediate the pro-osteoclastogenic effects of HMGB1 (Figure 1B). Consistent with 
this notion, S100A9 treatment in osteoblasts stimulated RAGE expression and promoted 
cytokine release; and S100A9-treated osteoblast CM increased osteoclast differentiation/
activity, whereas directly in osteoclasts S100A9 inhibited osteoclastogenesis [47].
Similar effects have also been found with other RAGE ligands. For example, while high 
levels of AGEs during chronic inflammation induces apoptosis and increases inflammatory 
cytokine release in osteoblasts/osteocytes, the direct effects of AGEs in osteoclasts is not as 
well understood. While some studies have suggested that AGEs induce osteoclast 
differentiation/activity, others have found that AGEs inhibit osteoclast differentiation/
activity. In pre-osteoclasts, AGE treatment inhibits fusion/differentiation and decreases 
resorption, whereas in mature osteoclasts treatment slightly increases differentiation/activity 
[82]. On the other hand, AGEs increase osteoblasts/osteocytes cytokine release, which may 
subsequently increase osteoclastogenesis. Consistently, high levels of AGE in bone are 
associated with increased osteoclast activity in humans, despite a lack of effect of AGEs on 
osteoclast activity in vitro [83].
Overall, these findings suggest that, at least at high doses/chronic exposure, RAGE ligands 
(AGEs, HMGB1, S100 proteins) may directly induce apoptosis and inhibit bone cell 
differentiation/activity (Figure 1). Additionally, these findings suggest that RAGE-ligand 
signaling-induced apoptosis in osteoblast/osteocytes stimulates cytokine release, which may 
subsequently induce osteoclast differentiation/activation.
RAGE and its Ligands in Bone Disease
In addition to their physiological roles, RAGE and its ligands are involved in various 
pathologies characterized by reduced bone mass and increased fragility/fracture. RAGE 
expression and its ligands are upregulated in numerous pathologies characterized by 
systemic inflammation, which are also associated with bone loss [3]. Consistently, as 
discussed above, elevated RAGE expression and increased circulating levels of RAGE 
ligands alter bone cell differentiation, activity, and viability pointing to the potential 
involvement of RAGE signaling in the onset of bone loss in these pathologies [4].
In particular, RAGE and its ligands have been linked to several diabetes-associated 
conditions and elevated levels of circulating AGEs and increased RAGE signaling are 
associated with osteoporosis in diabetes [36]. AGEs negatively affect bone metabolism in 
diabetes; and decrease bone healing in a mouse model of type 1 diabetes (T1D) [84]. 
Consistently, bone marrow MSC maintenance is impaired in mouse models of both T1D and 
T2D; and RAGE KO mice are resistant to the streptozotocin T1D-induced decreases in 
MSCs [69]. These pieces of evidence highlight the potential involvement of RAGE 
expression/signaling during the onset and progression of diabetes-related bone loss.
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RAGE as a Biomarker for Bone Disease/Osteoporosis
Due the presence of circulating soluble RAGE isoforms in serum/plasma, the diagnostic 
potential of sRAGE as a biomarker has been evaluated in various diseases [12]. However, to 
date the preventive and diagnostic potential of sRAGE in bone disease has been quite 
contradictory. Thus, no association between RAGE polymorphisms and bone fractures were 
detected in T2D patients, and no correlation between circulating sRAGE levels and 
osteoporosis was found [85].
However, findings from other studies have suggested that low levels of sRAGE may be 
indicative of bone disease and be associated with high bone resorption, due to the absence of 
the inhibitory decoy effects of sRAGE. Consistent with this possibility, low serum esRAGE 
levels is a risk factor for vertebral fractures [86]. Additionally, low serum sRAGE and 
S100A12 levels in juvenile idiopathic arthritis correlated with increased disease activity 
[87].
Several other recent studies have suggested that sRAGE levels may actually be elevated in 
osteoporotic patients. sRAGE levels were elevated in rheumatoid patients with high levels of 
bone and cartilage turnover prior to hormone replacement therapy (HRT) [88]. Following 
HRT, patients exhibited decreased sRAGE levels that correlated with increases in BMD. 
Additionally, elevated levels of circulating AGE and esRAGE were associated with 
increased bone turnover and hip fracture incidence in elderly men [89]. Further, circulating 
sRAGE levels significantly correlate with osteopenia and osteoporosis [90]. And, higher 
sRAGE levels positively associated with elevated FGF23 levels, a protein known to be 
elevated in osteoporotic patients. Interestingly, sRAGE levels also negatively correlated to 
BMI and leptin, suggesting sRAGE could be a biomarker indicative of both bone fragility 
and lipid metabolism. The authors of this study also speculated that elevated sRAGE could 
be a direct effect of increased MMP9 activity, suggesting that sRAGE may be an indicator of 
increased osteoclast activity rather than an inhibitor of bone resorption due to its decoy 
activity. Based on this notion, sRAGE may indicate high levels of bone turnover and may be 
higher when circulating DAMP levels are elevated. Interestingly, recent studies by our group 
found that esRAGE and TLR4, but not RAGE mRNA expression is increased in osteocyte 
enriched long bones of aged (21-month-old) compared to young (4-month-old) mice, 
suggesting that elevated membrane bound RAGE expression, at least in osteocytes, may not 
be responsible for promoting age-related bone loss and circulating sRAGE levels may 
actually be elevated in aging-induced osteoporosis.
Therapeutic Potential of Targeting RAGE and its Ligands
Based on the idea that chronic elevated RAGE signaling contributes to the onset/progression 
of bone disease in aging and conditions of increased inflammation, several studies have 
examined the effects of targeting/blocking RAGE and its ligands in bone. Due to its decoy 
inhibitory properties, the therapeutic potential of sRAGE has been examined by several 
groups [91]. Additionally, blockade of RAGE signaling by sRAGE administration has 
beneficial effects in mouse models of Alzheimer’s disease [92]. In MSCs, sRAGE 
transfection prevents HMGB1-induced inflammation [93]. Further, RAGE inhibition by 
sRAGE treatment also had protective effects on bone metabolism and diminished alveolar 
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bone loss in a mouse model of diabetic periodontal disease [91]. Despite the anti-
inflammatory effects following sRAGE administration, other studies have seen cell/tissue-
type specific pro-inflammatory effects with sRAGE [18, 22, 23].
In addition to sRAGE, numerous small-molecule inhibitors that target RAGE and its ligands 
have developed and evaluated over the last decade [8]. For example, the small molecule 
TTP488 (Azeliragon) inhibits RAGE ability to bind ligands, including AGEs, HMGB1, 
S100 proteins, and Aβ [94]. The effects of this compound in Alzheimer’s disease have been 
evaluated in both pre-clinical mouse models and clinical trials [95, 96]. In addition, 
screening a library of small molecule RAGE inhibitors, FPS-ZM1, a compound that inhibits 
RAGE-Aβ interactions was identified [97]. Pre-clinical studies with FPS-ZM1 showed 
beneficial effects in many disease states, including neuro-inflammation and cancer. 
Additionally, FPS-ZM1 has protective effects in bone by preventing RAGE-dependent 
mitochondrial dysfunction and apoptosis in osteoblasts and osteocytes [72, 78]. These 
findings highlight the therapeutic potential of small-molecule RAGE inhibitors to treat 
and/or prevent bone disease.
Conclusions
RAGE and its ligands play an important physiological role in the skeleton, and elevated 
levels of RAGE and its ligands are clearly related to various bone-related diseases. Despite 
the recent advances in this field, many remain questions unanswered: 1) What are the 
specific roles that RAGE and its ligands play in the various bone cell types under 
physiological and pathological conditions? 2) What is the therapeutic potential of RAGE and 
its ligands as pharmacological targets to prevent bone loss/fragility induced with aging and 
inflammatory diseases? 3) Could RAGE and its ligands provide diagnostic utility serving as 
biomarkers of bone disease progression and severity? Thus, while our understanding of 
RAGE signaling in the skeleton has improved, several key questions remain to be answered 
and warrant further investigation.
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Figure 1: RAGE ligands signaling in bone cells: direct and indirect effects.
Schematic illustration of the dose and bone cell-type specific effects of RAGE-ligand 
signaling in the skeleton. (A) Direct bone-cell type specific effects of low-dose/short-term 
and high-dose/chronic RAGE ligand exposure. (B) Indirect and paracrine-signaling bone 
microenvironment changes induced by RAGE ligand-signaling.
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